Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATEC NYSE:AVNS OTCMKTS:EDTXF NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATECAlphatec$7.68+2.7%$9.75$6.82▼$23.29$1.18B0.883.29 million shs2.43 million shsAVNSAvanos Medical$24.97-0.1%$21.02$9.30▼$25.49$1.17B1.561.13 million shs2.35 million shsEDTXFSpectral Diagnostics$1.00-1.7%$1.01$0.58▼$1.31$292.10M0.099,441 shs310 shsTNDMTandem Diabetes Care$18.03-3.1%$18.55$9.98▼$29.65$1.24B1.582.16 million shs2.36 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATECAlphatec0.00%-7.20%-28.28%-42.46%-39.19%AVNSAvanos Medical-0.38%+1.06%+1.37%+80.32%+107.39%EDTXFSpectral Diagnostics+0.21%+0.27%+2.04%+6.03%+69.26%TNDMTandem Diabetes Care-2.72%+27.92%-4.53%-20.55%-8.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATECAlphatec$7.68+2.7%$9.75$6.82▼$23.29$1.18B0.883.29 million shs2.43 million shsAVNSAvanos Medical$24.97-0.1%$21.02$9.30▼$25.49$1.17B1.561.13 million shs2.35 million shsEDTXFSpectral Diagnostics$1.00-1.7%$1.01$0.58▼$1.31$292.10M0.099,441 shs310 shsTNDMTandem Diabetes Care$18.03-3.1%$18.55$9.98▼$29.65$1.24B1.582.16 million shs2.36 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATECAlphatec0.00%-7.20%-28.28%-42.46%-39.19%AVNSAvanos Medical-0.38%+1.06%+1.37%+80.32%+107.39%EDTXFSpectral Diagnostics+0.21%+0.27%+2.04%+6.03%+69.26%TNDMTandem Diabetes Care-2.72%+27.92%-4.53%-20.55%-8.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATECAlphatec 2.75Moderate Buy$18.58141.97% UpsideAVNSAvanos Medical 1.00SellN/AN/AEDTXFSpectral Diagnostics 0.00N/AN/AN/ATNDMTandem Diabetes Care 2.57Moderate Buy$29.8465.51% UpsideCurrent Analyst Ratings BreakdownLatest EDTXF, ATEC, TNDM, and AVNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026TNDMTandem Diabetes Care Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Overweight$21.00 ➝ $27.005/28/2026TNDMTandem Diabetes Care CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$22.00 ➝ $17.005/27/2026TNDMTandem Diabetes Care The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.005/26/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026TNDMTandem Diabetes Care Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $25.005/11/2026TNDMTandem Diabetes Care BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold5/11/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026TNDMTandem Diabetes Care BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$56.00 ➝ $55.005/11/2026TNDMTandem Diabetes Care Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.00 ➝ $31.005/8/2026TNDMTandem Diabetes Care MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/7/2026ATECAlphatec BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $24.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATECAlphatec$787.08M1.50N/AN/A$0.08 per share96.00AVNSAvanos Medical$701.20M1.67$3.42 per share7.31$16.73 per share1.49EDTXFSpectral Diagnostics$1.75M166.91N/AN/A($0.17) per share-5.86TNDMTandem Diabetes Care$1.03B1.20N/AN/A$2.29 per share7.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATECAlphatec-$143.36M-$0.82N/A153.60N/A-15.93%-1,183.84%-15.83%7/30/2026 (Estimated)AVNSAvanos Medical-$72.90M-$1.61N/A26.56N/A-10.39%5.39%3.97%8/4/2026 (Estimated)EDTXFSpectral Diagnostics-$34.13M-$0.10N/AN/AN/A-1,378.12%N/A-581.29%8/7/2026 (Estimated)TNDMTandem Diabetes Care-$204.71M-$1.40N/A200.33N/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)Latest EDTXF, ATEC, TNDM, and AVNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026EDTXFSpectral Diagnostics-$0.0072-$0.01-$0.0028-$0.01$0.54 million$0.64 million5/7/2026Q1 2026TNDMTandem Diabetes Care-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million5/5/2026Q1 2026ATECAlphatec-$0.01-$0.22-$0.21-$0.22$197.51 million$192.11 million5/5/2026Q1 2026AVNSAvanos Medical$0.16$0.22+$0.06$0.11$170.00 million$182.20 million3/26/2026Q4 2025EDTXFSpectral Diagnostics-$0.0073-$0.0073N/A-$0.01$0.54 million$0.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATECAlphatecN/AN/AN/AN/AN/AAVNSAvanos MedicalN/AN/AN/AN/AN/AEDTXFSpectral DiagnosticsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATECAlphatec40.351.901.12AVNSAvanos Medical0.112.481.40EDTXFSpectral DiagnosticsN/A0.080.07TNDMTandem Diabetes Care4.543.583.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATECAlphatec66.35%AVNSAvanos Medical95.17%EDTXFSpectral DiagnosticsN/ATNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipATECAlphatec13.48%AVNSAvanos Medical2.33%EDTXFSpectral Diagnostics1.50%TNDMTandem Diabetes Care2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATECAlphatec700153.79 million133.06 millionOptionableAVNSAvanos Medical2,28746.83 million45.73 millionOptionableEDTXFSpectral Diagnostics29293.42 million289.02 millionNot OptionableTNDMTandem Diabetes Care2,50068.53 million67.09 millionOptionableEDTXF, ATEC, TNDM, and AVNS HeadlinesRecent News About These CompaniesTandem Diabetes Valuation: Is 1.1x Sales a Buy?June 3 at 12:26 PM | zacks.comTNDM Stock: What to Know About Tandem's 2026 ResetJune 2 at 12:01 PM | zacks.comTandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Score of 62 Tells InvestorsMay 28, 2026 | gurufocus.comTandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed?May 24, 2026 | finance.yahoo.comSilver Economy Investing: Why the Healthcare Giants Are in FocusMay 19, 2026 | zacks.comTandem Diabetes’s Q1 earnings call: Our top 5 analyst questionsMay 14, 2026 | msn.comTNDM stock down following Q1 earnings & revenue beat, gross margin upMay 14, 2026 | msn.comTNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin UpMay 14, 2026 | zacks.comTandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 12, 2026 | zacks.comTandem Diabetes Care, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comTandem Diabetes Care (NASDAQ:TNDM) Receives "Buy" Rating from Truist FinancialMay 11, 2026 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 11, 2026 | finance.yahoo.comTandem Diabetes Care, Inc. $TNDM Shares Acquired by Vanguard Group Inc.May 11, 2026 | marketbeat.comTandem Diabetes Care (TNDM) Gets a Buy from Piper SandlerMay 10, 2026 | theglobeandmail.comTandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call TranscriptMay 10, 2026 | seekingalpha.comTandem Diabetes Care Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comTandem to submit tubless pump to FDA with Street-beating Q1 on record pump shipmentsMay 8, 2026 | drugdeliverybusiness.comDTandem Diabetes Care Charts Growth Amid TransitionMay 8, 2026 | tipranks.comTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Earnings BeatMay 8, 2026 | marketbeat.comTNDM Q1 deep dive: Margin expansion and pipeline advances amid business model shiftMay 8, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDTXF, ATEC, TNDM, and AVNS Company DescriptionsAlphatec NASDAQ:ATEC$7.68 +0.20 (+2.67%) Closing price 04:00 PM EasternExtended Trading$7.50 -0.18 (-2.34%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.Avanos Medical NYSE:AVNS$24.96 -0.03 (-0.10%) Closing price 03:58 PM EasternExtended Trading$24.94 -0.02 (-0.10%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Spectral Diagnostics OTCMKTS:EDTXF$1.00 -0.02 (-1.70%) As of 09:42 AM EasternSpectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.Tandem Diabetes Care NASDAQ:TNDM$18.03 -0.57 (-3.06%) Closing price 04:00 PM EasternExtended Trading$18.31 +0.28 (+1.55%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
